Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

  • LAST PRICE
    8.8400
  • TODAY'S CHANGE (%)
    -0.6800 (-7.1429%)
  • Bid / Lots
    8.6100/ 6
  • Ask / Lots
    8.9700/ 2
  • Open / Previous Close
    9.4500 / 9.5200
  • Day Range
    8.7600
    9.5200
  • 52 Week Range
    8.7600
    30.5300
  • Volume
    1,384,455

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ZNTL
Zentalis Pharmaceuticals Inc
627.8M
-2.6x
---
AVBP
Arrivent Biopharma Inc
626.3M
0.0x
---
MLYS
Mineralys Therapeutics Inc
624.6M
-5.8x
---
GHRS
GH Research PLC
623.8M
-17.5x
---
PROK
ProKidney Corp
632.5M
-4.8x
---
OCS
Oculis Holding AG
550.3M
-6.4x
---
As of 2024-06-16

Company Information

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Contact Information

Headquarters
1359 Broadway, Suite 801NEW YORK, NY, United States 10018
Phone
212-433-3791
Fax
302-655-5049

Executives

Independent Chairman of the Board
David Johnson
President, Executive Director
Cam Gallagher
Chief Executive Officer, Director
Kimberly Blackwell
Chief Financial Officer, Treasurer
Melissa Epperly
Chief Operating Officer
Iris Roth

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$627.8M
Revenue (TTM)
$40.6M
Shares Outstanding
71.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.79
EPS
$-3.36
Book Value
$6.18
P/E Ratio
-2.6x
Price/Sales (TTM)
15.5
Price/Cash Flow (TTM)
---
Operating Margin
-639.35%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.